{{update|date=November 2013}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 436337708
| IUPAC_name = (1-(2-Morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone
| image = JWH-200.svg
| width = 180

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =
| legal_AU = S9
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Schedule I <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_DE = Anlage II
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 103610-04-4

| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9HN5J913P3


| ATC_prefix =
| ATC_suffix =
| PubChem = 10045570
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID      = 8221134

<!--Chemical data-->
| C=25 | H=24 | N=2 | O=2
| molecular_weight = 384.469 g/mol
| smiles = O=C(C1=CC=CC2=C1C=CC=C2)C3=CN(C4=C3C=CC=C4)CCN5CCOCC5
| StdInChI          = 1S/C25H24N2O2/c28-25(22-10-5-7-19-6-1-2-8-20(19)22)23-18-27(24-11-4-3-9-21(23)24)13-12-26-14-16-29-17-15-26/h1-11,18H,12-17H2
| StdInChIKey       = SZWYXJHTNGJPKU-UHFFFAOYSA-N

}}
'''JWH-200''' ('''WIN 55,225''')<ref>{{Cite journal |pmid= 9313864 |year= 1997 |last= Dutta |first= A. K., ''E. A. '' |last2= Ryan | first2= W. |last3= Thomas | first3= B. F. |last4= Singer | first4= M. |last5= Compton | first5= D. R. |last6= Martin | first6= B. R. |last7= Razdan | first7= R. K. |title= Synthesis, pharmacology, and molecular modeling of novel 4-alkyloxy indole derivatives related to cannabimimetic aminoalkyl indoles (AAIs) |volume= 5 |issue= 8 |pages= 1591–1600 |journal= Bioorganic & Medicinal Chemistry |doi= 10.1016/S0968-0896(97)00111-9 }}
</ref> is an [[analgesic]] chemical from the [[aminoalkylindole]] family that acts as a [[cannabinoid]] receptor agonist. Its [[Dissociation constant|binding affinity, ''K''<sub>i</sub>]] at the CB<sub>1</sub> receptor is 42&nbsp;nM, around the same as that of [[THC]],<ref>Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. ''Current Medicinal Chemistry'', 2005; 12: 1395-1411.</ref> but its analgesic potency ''in vivo'' was higher than that of other analogues with stronger CB<sub>1</sub> binding affinity ''in vitro'',<ref>{{cite journal |doi= 10.1021/jm00107a034 |last= Bell |first= MR|title= Antinociceptive (aminoalkyl)indoles |journal= Journal of Medicinal Chemistry |volume= 34 |issue= 3 |pages= 1099–1110 |pmid= 1900533 |display-authors=etal|year= 1991 }}</ref> around 3 times that of THC but with less sedative effect,<ref>{{cite journal |last= Compton |first= DR|year= 1992 |title= Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol |journal= Journal of Pharmacology and Experimental Therapeutics |volume= 263 |issue= 3 |pages= 1118–26 |pmid= 1335057 |display-authors=etal}}</ref> most likely reflecting favourable [[pharmacokinetic]] characteristics. It was discovered by, and named after, Dr. [[John W. Huffman]].

==Legal Status==
===Australia===
JWH-200 is considered a Schedule 9 prohibited substance in Australia under the [[Standard for the Uniform Scheduling of Medicines and Poisons|Poisons Standard]] (October 2015).<ref name="Poisons Standard">Poisons Standard October 2015 https://www.comlaw.gov.au/Details/F2015L01534</ref> A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.<ref name="Poisons Standard" />

===United States===
The US [[DEA]] temporarily declared JWH-200 a [[Schedule I (US)|schedule I controlled substance]] on 1 March 2011 through 76 FR 11075, and permanently instated the same schedule on 9 July 2012 in the Section 1152 of the [[Food and Drug Administration Safety and Innovation Act]].<ref>{{cite web|title=Schedules of Controlled Substances: Temporary Placement of Four Synthetic Cannabinoids Into Schedule I|url=http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0110_10.htm|publisher=DEA Office of Diversion Control|accessdate=11 March 2014}}</ref> {{Asof|2015|July|16}}, the drug is a controlled substance in Canada.<ref>http://www.gazette.gc.ca/rp-pr/p2/2015/2015-07-29/html/sor-dors192-eng.php</ref>

==See also==
* [[JWH-018]]
* [[JWH-073]]
* [[CP-47,497]]
* [[HU-210]]
* [[A-796,260]]
* [[MEPIRAPIM]]
* [[WIN 55,212-2]]

==References==
{{Reflist}}

{{Cannabinoids}}
{{Hallucinogens}}

[[Category:Aminoalkylindoles]]
[[Category:Designer drugs]]
[[Category:JWH cannabinoids]]
[[Category:Morpholines]]
[[Category:Naphthoylindoles]]
[[Category:WIN compounds]]

{{cannabinoid-stub}}